Cancer Research

Giannis Mountzios: Shedding Light on Factors Influencing Treatment Sequence in BRAF Mutant NSCLC

Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, shared a post on X about a paper by Marcel Wiesweg et al. published in the Journal of Thoracic Oncology:

“Excellent report in Journal of Thoracic Oncology⁦⁩ shedding light on factors influencing treatment sequence in BRAF mutant NSCLC.

  • Identical OS 28 m with TKI combo vs chemo/IO
  • Gender impact! F > M with BRAF/MEK but F=M with IO (confounder: smoking?).”

Title: Treatment sequences in BRAF-V600-mutated non-small cell lung cancer: First-line targeted therapy versus first-line (chemo-) immunotherapy

Authors: Marcel Wiesweg, Ali Alaffas, Anna Rasokat, Felix Carl Saalfeld, Maximilian Rost, Christin Assmann, Franziska Herster, Moritz Hilbrandt, Frank Griesinger, Anna Kron, Julia Roeper, Franziska Glanemann, Cornelia Kropf-Sanchen, Martin Reck, Jonas Kulhavy, Albrecht Stenzinger, Jürgen Wolf, Martin Sebastian, Martin Schuler, Martin Wermke, Nikolaj Frost, Hans-Georg Kopp, Petros Christopoulos, Matthias Scheffler.

Giannis Mountzios: Shedding Light on Factors Influencing Treatment Sequence in BRAF Mutant NSCLC

Read the Full Article in Journal of Thoracic Oncology.

More posts featuring Giannis Mountzios.

Albrecht Stenzinger Ali Alaffas Anna Kron Anna Rasokat cancer Christin Assmann Cornelia Kropf-Sanchen Felix Carl Saalfeld Frank Griesinger Franziska Glanemann Franziska Herster Giannis Mountzios Hans-Georg Kopp immunotherapy Jonas Kulhavy Journal of Thoracic Oncology Julia Roeper Jürgen Wolf Marcel Wiesweg Martin Reck Martin Schuler Martin Sebastian Martin Wermke Matthias Scheffler Maximilian Rost Moritz Hilbrandt Nikolaj Frost non small cell lung cancer NSCLC OncoDaily Oncology Petros Christopoulos